Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMLK2QH)

Drug Name
Nateglinide Drug Info
Synonyms
Fastic; IPCCPA; Senaglinide; Starlix; Starsis; Trazec; Nateglinide [INN]; Novartis brand of nateglinide; DJN 608; A-4166; AY-4166; DJN-608; Nate-glinide; Starlix (TN); YM-026; SDZ-DJN-608; N-((4-isopropylcyclohexyl)carbonyl)phenylalanine; Nateglinide, (D-Phe)-isomer; Nateglinide, (cis,D-Phe)-isomer; N-{[4-(propan-2-yl)cyclohexyl]carbonyl}phenylalanine; N-{[trans-4-(propan-2-yl)cyclohexyl]carbonyl}-D-phenylalanine; (2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid; 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid
Therapeutic ClassHypoglycemic Agents
Cross-matching ID
PubChem CID
5311309
ChEBI ID
CHEMBL31897
CAS Number
CAS 105816-04-4
TTD Drug ID
D06PSS
VARIDT Drug ID
DR00407
INTEDE Drug ID
DR1132
ACDINA Drug ID
D00458

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Galactose metabolism -1.66 4.92e-2 26/31 (83.87%) LALBA;HK2;G6PC3;...
IL-17 signaling pathway -1.69 3.39e-2 84/94 (89.36%) MUC5AC;FOS;TRAF3IP2;...
Type I diabetes mellitus -1.69 3.65e-2 38/43 (88.37%) HLA-DMB;IFNG;HLA-E;...
Bladder cancer -1.70 3.95e-2 40/41 (97.56%) ERBB2;TP53;MAPK3;...
Glycolysis / Gluconeogenesis -1.70 4.07e-2 56/67 (83.58%) GPI;HK2;G6PC3;...
Rheumatoid arthritis -1.71 4.21e-2 78/93 (83.87%) HLA-DPA1;ATP6V0E1;CD86;...
Neutrophil extracellular trap formation -1.71 4.68e-2 101/189 (53.44%) PRKCA;PIK3CB;FPR2;...
Graft-versus-host disease -1.73 4.61e-2 32/42 (76.19%) GZMB;IL1B;CD28;...
Allograft rejection -1.73 4.89e-2 32/38 (84.21%) HLA-DMB;IFNG;HLA-E;...
Autoimmune thyroid disease -1.79 1.98e-2 46/53 (86.79%) TPO;HLA-DMB;TSHB;...
Pentose phosphate pathway -1.79 2.37e-2 25/30 (83.33%) GPI;G6PD;PGLS;...
Primary bile acid biosynthesis -1.86 6.58e-3 15/17 (88.24%) BAAT;SLC27A5;AKR1D1;...
Antigen processing and presentation -1.87 8.78e-3 60/78 (76.92%) HSPA1L;IFNG;HSPA6;...
Asthma -1.92 6.58e-3 25/31 (80.65%) HLA-DPA1;FCER1A;HLA-DRA;...
Cholesterol metabolism -1.96 1.32e-2 44/50 (88%) ABCB11;LDLR;NPC1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 10uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 10uM 24H